RTF

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, February 25, 2023
Maker, Overalls, Memorial Sloan Kettering Cancer Center, Prospectus, Observation, Registration statement, Neuroblastoma, IPO, Safety, Therapy, Central nervous system, Advisory Committee, ESS, LM, RTF, Patient, Database, MRI, NB, Biologics license application, IBM, Class, Sale, Knowledge, Spinal cord, Register, NYSE, Partnership, CSF, Brain, OS, CNS, Letter, ORR, Bank statement, Placebo, Form 10-K, Rule, ESI, Person, Marketing, News, Shareholder, Survival, CFR, BLA, Risk, FDA, Element, P.C, Radiation, Form 10-Q, Disclosure, Vaccine, Medical imaging, Pharmaceutical industry, Nursing, Medical device, Cryptocurrency, Audit, Security (finance), Tobacco, Defendant, Plaintiff, Form

According to Y-mAbs’s 2021 Form 10-K (at 27), there are approximately 700 children diagnosed with neuroblastoma (NB) in the United States each year.

Key Points: 
  • According to Y-mAbs’s 2021 Form 10-K (at 27), there are approximately 700 children diagnosed with neuroblastoma (NB) in the United States each year.
  • The efficacy population in Study 03-133 consisted of a subset of 94 patients ages 0.9 to 13 years.
  • As of the time this Complaint was filed, Bioventus's Class A common stock continues to trade below the $13.00 per share Offering price, damaging investors.
  • The market price of IBM securities declined sharply upon public disclosure of the facts alleged herein to the injury of Plaintiff and Class members.

Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)

Retrieved on: 
Tuesday, February 14, 2023
Bias, Advisory Committee, Therapy, District court, Investment, Food and Drug Administration, Action Replay, Patient, Advertising, News, Food, Letter, CNS, Aerospace, Survival, RTF, Marketing, FDA, Court, Cancer, Pharmaceutical industry, Security (finance)

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the common stock of Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB) between October 6, 2020 and October 28, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.
  • Y-mAbs is a clinical-stage biopharmaceutical company focused on developing antibody therapeutics and medicines for the treatment of cancer patients of all ages.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, February 14, 2023
Maker, Bank statement, Prospectus, Rule, CFR, Safety, NYSE, LM, Placebo, CSF, Person, Partnership, Memorial Sloan Kettering Cancer Center, NB, Brain, Element, Form 10-Q, Radiation, News, Form 10-K, CNS, Risk, IPO, ORR, Knowledge, Survival, RTF, Marketing, Neuroblastoma, FDA, Observation, ESI, Spinal cord, IBM, Advisory Committee, OS, MRI, Patient, Disclosure, Database, Sale, Letter, Therapy, Central nervous system, BLA, Registration statement, Register, Biologics license application, P.C, ESS, Class, Overalls, Shareholder, Vaccine, Medical imaging, Pharmaceutical industry, Nursing, Medical device, Cryptocurrency, Audit, Security (finance), Tobacco, Defendant, Plaintiff, Form

According to Y-mAbs’s 2021 Form 10-K (at 27), there are approximately 700 children diagnosed with neuroblastoma (NB) in the United States each year.

Key Points: 
  • According to Y-mAbs’s 2021 Form 10-K (at 27), there are approximately 700 children diagnosed with neuroblastoma (NB) in the United States each year.
  • The efficacy population in Study 03-133 consisted of a subset of 94 patients ages 0.9 to 13 years.
  • As of the time this Complaint was filed, Bioventus's Class A common stock continues to trade below the $13.00 per share Offering price, damaging investors.
  • The market price of IBM securities declined sharply upon public disclosure of the facts alleged herein to the injury of Plaintiff and Class members.

Y-mAbs Therapeutics, Inc. (YMAB) Investor Alert: Robbins LLP Reminds Shareholders of Class Action Against Y-mAbs Therapeutics, Inc.

Retrieved on: 
Friday, January 27, 2023
Class Action Lawsuit, Professional Services, Legal, Therapy, B7-H3, Biologics license application, Patient, Efficacy, Committee, News, Database, Letter, CNS, Memorial Sloan Kettering Cancer Center, Complaint, RTF, Marketing, Viability, FDA, Cancer, Pharmaceutical industry

Y-mAbs is a clinical-stage biopharmaceutical company focused on developing antibody therapeutics and medicines for the treatment of cancer patients of all ages.

Key Points: 
  • Y-mAbs is a clinical-stage biopharmaceutical company focused on developing antibody therapeutics and medicines for the treatment of cancer patients of all ages.
  • Shareholders who want to act as lead plaintiff for the class must file their papers by March 20, 2023.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • On this news, Y-mAbs common shares fell $11.56 per share, to close at $3.61 per share on October 31, 2022.

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Y-mAbs Therapeutics, Inc. (YMAB)

Retrieved on: 
Friday, January 20, 2023
Class Action Lawsuit, Professional Services, Legal, Therapy, B7-H3, Biologics license application, Patient, Efficacy, Committee, News, Database, Letter, CNS, Memorial Sloan Kettering Cancer Center, Complaint, RTF, Marketing, Viability, FDA, Cancer, Pharmaceutical industry

The Class: Robbins LLP informs investors that a shareholder filed a class action on behalf of all investors who purchased shares of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) common stock between October 6, 2020 and October 28, 2022, for violations of the Securities Exchange Act of 1934.

Key Points: 
  • The Class: Robbins LLP informs investors that a shareholder filed a class action on behalf of all investors who purchased shares of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) common stock between October 6, 2020 and October 28, 2022, for violations of the Securities Exchange Act of 1934.
  • Y-mAbs is a clinical-stage biopharmaceutical company focused on developing antibody therapeutics and medicines for the treatment of cancer patients of all ages.
  • Shareholders who want to act as lead plaintiff for the class must file their papers by March 30, 2023.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Return to Freedom calls on Congress to stop the slaughter of American horses

Retrieved on: 
Monday, February 20, 2023
Bureau of Land Management, Organization, House, BLM, Attention, Blood, Water, Breeder, New York Racing Association, Bureau, Jockey Club, Horse, Retirement, United States Forest Service, Pain, Breeders' Cup Classic, Aftercare, Language, Terror, Agriculture, Food, Health, Jockey Club (United States), Congress, RTF, Agricultural Appropriations Act of 1922, Education, Japan Bloodhorse Breeders' Association, Frank DeMayo, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Livestock, Animal husbandry

19,989 American horses were shipped to slaughter plants in Mexico or Canada in 2022, according to government statistics.

Key Points: 
  • 19,989 American horses were shipped to slaughter plants in Mexico or Canada in 2022, according to government statistics.
  • Return to Freedom Wild Horse Conservation, a national nonprofit advocacy organization, strongly urges Congress to finally pass a permanent ban on horse slaughter in the United States and on the export of American horses for purposes of slaughter.
  • "More than 90 percent of American horses shipped to slaughter were in good condition before suffering grueling journeys to foreign slaughterhouses, according to one government study," said Neda DeMayo, president of Return to Freedom (RTF).
  • During the last Congress, a proposed horse slaughter ban received the backing of 225 bipartisan House cosponsors before special interests stymied its progress.

Y-mAbs Therapeutics, Inc. (YMAB) Class Action Notice: Robbins LLP Urges Shareholders to Contact the Firm for Information Regarding Their Rights

Retrieved on: 
Thursday, February 9, 2023
Marketing, RTF, CNS, Complaint, Efficacy, Memorial Sloan Kettering Cancer Center, Cancer, Database, Therapy, Biologics license application, Patient, B7-H3, FDA, Committee, Viability, Letter, News, Pharmaceutical industry

Y-mAbs is a clinical-stage biopharmaceutical company focused on developing antibody therapeutics and medicines for the treatment of cancer patients of all ages.

Key Points: 
  • Y-mAbs is a clinical-stage biopharmaceutical company focused on developing antibody therapeutics and medicines for the treatment of cancer patients of all ages.
  • Shareholders who want to act as lead plaintiff for the class must file their papers by March 20, 2023.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • On this news, Y-mAbs common shares fell $11.56 per share, to close at $3.61 per share on October 31, 2022.

Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)

Retrieved on: 
Tuesday, February 7, 2023
Marketing, RTF, Food, Food and Drug Administration, CNS, The Legal 500, Advertising, Cancer, Bias, Court, Therapy, Survival, Advisory Committee, Labour government, Patient, FDA, District court, Investment, Aerospace, Letter, News, Medical device, Pharmaceutical industry, Security (finance)

NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the common stock of Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB) between October 6, 2020 and October 28, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Joseph R. Seidman, Jr. at (877) 779-1414 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.
  • Y-mAbs is a clinical-stage biopharmaceutical company focused on developing antibody therapeutics and medicines for the treatment of cancer patients of all ages.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Y-mAbs Therapeutics, Inc. (YMAB) Investor Alert: Robbins LLP Reminds Shareholders of Lead Plaintiff Deadline in Class Action Against Y-mAbs Therapeutics, Inc.

Retrieved on: 
Thursday, February 2, 2023
Marketing, RTF, CNS, Complaint, Efficacy, Memorial Sloan Kettering Cancer Center, Cancer, Database, Therapy, Biologics license application, Patient, B7-H3, FDA, Committee, Viability, Letter, News, Pharmaceutical industry

Y-mAbs is a clinical-stage biopharmaceutical company focused on developing antibody therapeutics and medicines for the treatment of cancer patients of all ages.

Key Points: 
  • Y-mAbs is a clinical-stage biopharmaceutical company focused on developing antibody therapeutics and medicines for the treatment of cancer patients of all ages.
  • The Company's lead product candidate is Omburtamab, a murine monoclonal antibody that targets B7-H3, an immune checkpoint molecule that is widely expressed in tumor cells of several cancer types.
  • Shareholders who want to act as lead plaintiff for the class must file their papers by March 20, 2023.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)

Retrieved on: 
Tuesday, January 31, 2023
Marketing, RTF, Food, Food and Drug Administration, CNS, The Legal 500, Advertising, Cancer, Bias, Court, Therapy, Survival, Advisory Committee, Labour government, Patient, FDA, District court, Investment, Aerospace, Letter, News, Tobacco, Pharmaceutical industry, Security (finance)

NEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the common stock of Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB) between October 6, 2020 and October 28, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.
  • Y-mAbs is a clinical-stage biopharmaceutical company focused on developing antibody therapeutics and medicines for the treatment of cancer patients of all ages.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.